Qiagen (QGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a chang ...

文章核心观点 - 公司与蒙大拿大学的雪山分子人类学实验室建立长期合作关系,共同利用下一代测序技术和法医遗传学家谱学技术,为失踪和被谋杀的原住民以及未确认身份的遗骸提供法医服务 [1][2][4][5] - 公司的技术可以从严重退化或污染的DNA样本中获得有价值的调查线索,有助于解决更多案件,为受影响家庭带来解决 [7] - 全球人类识别市场预计将从2024年的0.8亿美元增长到2029年的1.3亿美元,年复合增长率为10.7%,这为公司的合作带来了良好的市场前景 [8] 公司概况 - 公司在2024年6月推出了35种新的微生物DNA检测试剂,并推出了新的数字PCR定制试剂设计工具,进一步丰富了产品线 [9] - 公司的QIAstat-Dx胃肠道检测板2号获得FDA批准,将在美国推出 [10] - 过去一年公司股价下跌13.4%,低于同行业7.6%的跌幅 [11] - 公司目前评级为持有(Zacks Rank 3) [12] 行业概况 - 全球人类识别市场规模预计将从2024年的0.8亿美元增长到2029年的1.3亿美元,年复合增长率为10.7%,主要受益于调查人员对DNA分析的认识提高、犯罪率上升以及法医实验室的建立 [8]

Missoula, Montana, and Venlo, the Netherlands, July 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics. The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) using DNA technologies such as next-generation sequencing (NGS) and forensic investigati ...

Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: ...

QIAGEN N.V. (QGEN) recently lauded the new guidelines in the United States that recommend screening at- risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QuantiFERON-TB Gold Plus (QFT-Plus). The latest guidelines from the American Academy of Pediatrics (AAP) highlight testing for TB with modern interferon-gamma release assays (IGRAs). With this development, the company aims for its market-leading QFT-Plus to be a gold standard for blood-based tuberculosis ...

Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus (QFT-Plus). The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gam ...

Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus (QFT-Plus). The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gam ...

文章核心观点 - QIAGEN推出了QCI Interpret软件的新版本,提升了性能和可扩展性,加快了实验室的周转时间、诊断产出和结果质量[1][3][6][7] - QCI Interpret已经分析和解释了超过400万例肿瘤和遗传性疾病的NGS患者检测样本,成为全球各类实验室的首选[2] - QCI Interpret新版本增强了人工智能功能,包括文献搜索和表型驱动的排序,提高了工作流的可扩展性和检测菜单的扩展性,并增加了批量变异评估等功能[3][4] - QCI Interpret可以帮助实验室提高生产力、效率和可扩展性,应对不断增长的检测量,同时保持高质量结果[7] 行业概况 - 全球临床决策支持系统市场预计2023年达到53亿美元,未来8年将以10.8%的复合年增长率增长[8] - 这些系统有助于改善患者预后、降低整体医疗成本,在个体化医疗中发挥关键作用[9] 公司动态 - QIAGEN的QCI Interpret软件最新版本获得欧盟IVDR认证,成为首个获此认证的NGS解释平台[10] - 过去一年QGEN股价下跌7.8%,低于行业11.7%的跌幅[11] - QIAGEN目前评级为持有[12] - 同行业中Hims & Hers Health、Medpace和ResMed表现较好[13][14][16][17]

QIAGEN N.V. (QGEN) recently launched 35 new wet-lab tested dPCRs for its digital PCR (dPCR) platform QIAcuity. The new assays are available on the GeneGlobe research platform and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs). The latest development further strengthens QIAGEN's position as a leader in microbial detection and analysis. This is also likely to significantly boost its Life Sciences bu ...

Venlo, the Netherlands, and New York, June 17, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) will announce today at its Capital Markets Day a commitment to deliver solid profitable growth through 2028 – led by about 7% compound annual sales growth (CAGR) at constant exchange rates (CER) during the four-year period and achieving at least a 31% CER adjusted operating income margin in 2028. The event, which starts at 12:00 New York time / 17:00 London time / 18:00 Frankfurt time ...